SBIR-STTR Award

Cascade Rolling Circle Amplification For Dna Diagnostics
Award last edited on: 6/12/08

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$844,658
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
David D Thomas

Company Information

Oncor Inc

209 Perry Parkway
Gaithersburg, MD 20877
   (301) 963-3500
   N/A
   www.oncor.com
Location: Single
Congr. District: 06
County: Montgomery

Phase I

Contract Number: 1R43AI042481-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1997
Phase I Amount
$99,500
Many current nucleic acid amplification systems for detecting pathogenic agents may not yield consistent results because optimal amplification conditions vary with each target sequence. Cascade rolling circle amplification (CRCA) is a novel isothermal amplification system that uses generic primers to amplify circularized probes instead of the target. It is rapid, highly sensitive, and easily multiplexed, consistently yielding over a billion-fold amplification within one hour without using a thermocycler. If one of the primers is an energy transfer-labeled primer, homogeneous fluorescence detection of the CRCA product is possible within a closed system. The speed and ease of the assay make this technology suitable for field work or use in developing countries, as well as for simpler automation in diagnostic applications. The feasibility of this system has been demonstrated in preliminary experiments. Phase I objectives include optimization of ligation and amplification conditions to achieve maximum signal strength and sensitivity, and optimization of energy transfer-labeled primer structures that yield the highest fluorescence signal to background ratio without compromising amplification efficiency. The speed and sensitivity of the proposed method will be compared with traditional techniques using a pathogenic target Phase II studies will focus on clinical applications of this system. Proposed commercial applications: This amplification and detection system can form the basis of any DNA diagnostic procedure where the presence or absence of a specific nucleic and target sequence is determined, such as an infectious disease agent, inherited germline mutation, or somatic mutation in a cancer screening test The assay is highly sensitive, fast and simple, and we estimate that it will be less costly than current methods. Because it can be performed in a closed system, false-positive results from carry-over contamination will be minimized. The system is readily amenable to simple automation.

Thesaurus Terms:
DNA, diagnosis design /evaluation, diagnosis quality /standard, genetic marker, method development, nucleic acid probe chemical transfer reaction, macromolecule, nucleic acid sequence, rapid diagnosis, thermodynamics fluorescenceNational Institute of Allergy and Infectious Diseases (NIAID)

Phase II

Contract Number: 2R44AI042481-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1999
(last award dollars: 2000)
Phase II Amount
$745,158

DESCRIPTION (Applicant's abstract): A novel isothermal DNA amplification technique has been developed called cascade rolling circle amplification (CRCA). This method is simple, rapid, and highly sensitive, achieving over a billion-fold amplification within one hour. By making one of the primers an energy transfer-labeled primer that generates a fluorescent signal only when incorporated into the amplicon, CRCA products can be detected within a closed system. These features make this technology suitable for a variety of diagnostic applications including both automated platforms and point-of-care field devices. Phase I research has demonstrated the feasibility of CRCA for DNA diagnostics, including detection of pathogenic agents. The objectives of this Phase II project include i) improvements in the assay to make the technology more adaptable to a variety of platforms, ii) development of multiplex assay using energy transfer-labeled primers of different colors, iii) optimizing the system for real-time detection to accurately quantitate target sequences, iv) adapting CRCA to a point-of-care diagnostic platform that is non-fluorescence based, and v) adapting the technology to an array platform. Long-range objectives include implementing CRCA in an automated amplification/detection system and developing broad applications for the point-of-care diagnostic market PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Dna Primer, Diagnosis Design /Evaluation, Fluorescence Resonance Energy Transfer, Genetic Technique, Molecular Cloning, Technology /Technique Development Genetic Screening